Positive News SentimentPositive NewsNASDAQ:PRVB Provention Bio (PRVB) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$24.98▼$25.0050-Day Range$23.74▼$24.9852-Week Range$3.18▼$25.00Volume9.12 million shsAverage Volume2.28 million shsMarket Capitalization$2.37 billionP/E RatioN/ADividend YieldN/APrice Target$22.83 ProfileProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Provention Bio MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside8.6% Downside$22.83 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$53.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.72) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.58 out of 5 starsMedical Sector851st out of 981 stocksPharmaceutical Preparations Industry403rd out of 464 stocks 2.2 Analyst's Opinion Consensus RatingProvention Bio has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.83, Provention Bio has a forecasted downside of 8.6% from its current price of $24.98.Amount of Analyst CoverageProvention Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PRVB. Previous Next 0.0 Dividend Strength Dividend YieldProvention Bio does not currently pay a dividend.Dividend GrowthProvention Bio does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreProvention Bio has received a 74.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for the autoimmune system" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Provention Bio is -0.54. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added Provention Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Provention Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,274,152.00 in company stock.Percentage Held by Insiders13.10% of the stock of Provention Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 37.39% of the stock of Provention Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Provention Bio are expected to grow in the coming year, from ($1.72) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Provention Bio is -16.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Provention Bio is -16.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProvention Bio has a P/B Ratio of 17.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Provention Bio (NASDAQ:PRVB) StockProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Read More Receive PRVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provention Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address PRVB Stock News HeadlinesMay 12, 2023 | americanbankingnews.comProvention Bio, Inc. (NASDAQ:PRVB) Receives Average Recommendation of "Hold" from BrokeragesMay 1, 2023 | finance.yahoo.comSanofi/Provention: innovative diabetes drug is a good fitJune 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>April 29, 2023 | finance.yahoo.comThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%April 28, 2023 | seekingalpha.comSanofi completes Provention Bio acquisitionApril 27, 2023 | finance.yahoo.comEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineApril 27, 2023 | finanznachrichten.deSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 26, 2023 | seekingalpha.comProvention Bio gains after HSR waiting period for Sanofi deal expiredJune 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>April 26, 2023 | benzinga.comPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 22, 2023 | finance.yahoo.comPRVB Apr 2023 23.000 putApril 21, 2023 | americanbankingnews.comProvention Bio, Inc. (NASDAQ:PRVB) Major Shareholder Sells $53,274,151.68 in StockApril 15, 2023 | americanbankingnews.comProvention Bio, Inc. (NASDAQ:PRVB) Receives $22.83 Consensus Price Target from BrokeragesApril 11, 2023 | msn.comSanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More InformationApril 5, 2023 | americanbankingnews.comFY2023 EPS Estimates for Provention Bio, Inc. (NASDAQ:PRVB) Decreased by AnalystApril 2, 2023 | finance.yahoo.comProvention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 27, 2023 | bizjournals.comGaithersburg’s Novavax locks in consulting deal with outgoing R&D headMarch 21, 2023 | americanbankingnews.comBrokerages Set Provention Bio, Inc. (NASDAQ:PRVB) Target Price at $22.83March 17, 2023 | benzinga.com(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?March 16, 2023 | finance.yahoo.comQ4 2022 MacroGenics Inc Earnings CallMarch 15, 2023 | benzinga.comProvention Bio's Earnings OutlookMarch 14, 2023 | msn.comSMBC Nikko Downgrades Provention Bio (PRVB)March 14, 2023 | msn.comJefferies Downgrades Provention Bio (PRVB)March 14, 2023 | proactiveinvestors.comProvention Bio shares soar after Sanofi agrees to buy company in $2.9B cash dealMarch 14, 2023 | benzinga.comShort Volatility Alert: Provention Bio IncMarch 14, 2023 | markets.businessinsider.com4 Analysts Have This to Say About Provention BioMarch 13, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with SanofiSee More Headlines PRVB Company Calendar Last Earnings3/29/2023Today6/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRVB CUSIPN/A CIK1695357 Webwww.proventionbio.com Phone(908) 428-9136FaxN/AEmployees82Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.83 High Stock Price Forecast$25.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside-8.6%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,570,000.00 Net Margins-880.69% Pretax Margin-984.54% Return on Equity-103.36% Return on Assets-69.08% Debt Debt-to-Equity Ratio0.19 Current Ratio1.93 Quick Ratio1.92 Sales & Book Value Annual Sales$12.90 million Price / Sales183.54 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book17.84Miscellaneous Outstanding Shares94,780,000Free Float82,365,000Market Cap$2.37 billion OptionableNot Optionable Beta2.47 Key ExecutivesAshleigh W. PalmerChief Executive Officer & DirectorChristina YiChief Operating OfficerThierry ChaucheChief Financial OfficerFrancisco LeonChief Scientific OfficerEleanor Leni RamosChief Medical OfficerKey CompetitorsMirati TherapeuticsNASDAQ:MRTXCorcept TherapeuticsNASDAQ:CORTViking TherapeuticsNASDAQ:VKTXCureVacNASDAQ:CVACAmphastar PharmaceuticalsNASDAQ:AMPHView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 202,015 shares on 6/1/2023Ownership: 0.213%ProShare Advisors LLCBought 12,362 shares on 5/26/2023Ownership: 0.029%Water Island Capital LLCBought 953,407 shares on 5/25/2023Ownership: 1.006%Mint Tower Capital Management B.V.Bought 56,790 shares on 5/24/2023Ownership: 0.060%Putnam Investments LLCBought 16,106 shares on 5/22/2023Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions PRVB Stock - Frequently Asked Questions Should I buy or sell Provention Bio stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Provention Bio in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PRVB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRVB, but not buy additional shares or sell existing shares. View PRVB analyst ratings or view top-rated stocks. What is Provention Bio's stock price forecast for 2023? 7 Wall Street research analysts have issued 1-year price objectives for Provention Bio's shares. Their PRVB share price forecasts range from $18.00 to $25.00. On average, they expect the company's stock price to reach $22.83 in the next year. This suggests that the stock has a possible downside of 8.6%. View analysts price targets for PRVB or view top-rated stocks among Wall Street analysts. How were Provention Bio's earnings last quarter? Provention Bio, Inc. (NASDAQ:PRVB) announced its quarterly earnings results on Wednesday, March, 29th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.07. The business earned $10.81 million during the quarter, compared to analysts' expectations of $7.23 million. Provention Bio had a negative net margin of 880.69% and a negative trailing twelve-month return on equity of 103.36%. What ETFs hold Provention Bio's stock? ETFs with the largest weight of Provention Bio (NASDAQ:PRVB) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ProShares Merger ETF (MRGR), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), IQ Merger Arbitrage ETF (MNA), Invesco DWA SmallCap Momentum ETF (DWAS), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Provention Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Provention Bio investors own include NVIDIA (NVDA), OPKO Health (OPK), Amarin (AMRN), QUALCOMM (QCOM), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Axsome Therapeutics (AXSM), Fulcrum Therapeutics (FULC) and AbbVie (ABBV). What is Provention Bio's stock symbol? Provention Bio trades on the NASDAQ under the ticker symbol "PRVB." Who are Provention Bio's major shareholders? Provention Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sessa Capital IM L.P. (9.37%), BlackRock Inc. (5.98%), State Street Corp (1.83%), Geode Capital Management LLC (1.52%), Water Island Capital LLC (1.01%) and Pictet Asset Management SA (0.81%). Insiders that own company stock include Andrew T Drechsler, Ashleigh Palmer, Eleanor Ramos, Francisco Leon, Jason Hoitt and Sessa Capital (Master), LP. View institutional ownership trends. What is Provention Bio's stock price today? One share of PRVB stock can currently be purchased for approximately $24.98. How much money does Provention Bio make? Provention Bio (NASDAQ:PRVB) has a market capitalization of $2.37 billion and generates $12.90 million in revenue each year. The company earns $-113,570,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis. How can I contact Provention Bio? Provention Bio's mailing address is P.O. BOX 666, OLDWICK NJ, 08858. The official website for the company is www.proventionbio.com. The company can be reached via phone at (908) 428-9136 or via email at kimberly@argotpartners.com. This page (NASDAQ:PRVB) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provention Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.